Hantavirus Survivors: Recovery and Long-Term Effects

Most people who survive hantavirus pulmonary syndrome recover, but often more slowly than the illness itself suggests. In the only lung-function follow-up, breathlessness on exertion lasted one to two years in 7 of 9 New Mexico survivors and 6 of 14 in Panama, though the authors found it resolves in almost all patients in the end. In Chile, 13 of 21 survivors of intensive care said they had not fully recovered three to six months later. Antibodies last for years, and no second infection with the same hantavirus has been documented. The studies are small and none of them has a control group, so this page gives each one with its size and its limits.

Last reviewed: November 9, 2026  |  Sources: CDC; Gracia et al. Lung 2010; Pergam et al. Am J Trop Med Hyg 2009; Valenzuela et al. Viruses 2025; Ye et al. and Valdivieso et al. Emerg Infect Dis 2004, 2006; Ferrés et al. Lancet Infect Dis 2024; Puumala cohorts from Finland, Sweden and Germany

The Evidence at a Glance

Hantavirus pulmonary syndrome is rare, so survivor studies are small. A 2026 scoping review of Andes virus disease put it plainly: "Long-term outcomes are poorly characterized" (Fama et al., Clin Microbiol Infect 2026). These are the studies of the American form that exist:

HPS = hantavirus pulmonary syndrome (also called hantavirus cardiopulmonary syndrome). Sin Nombre virus causes most US cases; Andes virus most cases in Chile and Argentina; Choclo virus the cases in Panama. Full citations under Sources.
StudyWhoWhen measuredWhat it foundLimits
Gracia 2010, Lung9 Sin Nombre survivors (New Mexico), 14 Choclo survivors (Panama)Up to 8 yearsBreathlessness on exertion for 1–2 years in 77% (New Mexico) and 43% (Panama); reduced mid-expiratory airflow commonConvenience sample, no controls
Valenzuela 2025, Viruses21 Andes survivors in Chile, 2021–24; 11 had ECMO3–6 months61.9% reported incomplete recovery; fatigue in 81%Intensive-care survivors only, no controls
Pergam 2009, Am J Trop Med Hyg30 Sin Nombre survivors, New MexicoFrom a median 7.4 months, then yearlyHalf had protein in the urine; 53% met a definition of chronic kidney diseaseNo controls; the authors say only that kidney effects "may occur"
Hopkins 1998, J Int Neuropsychol Soc2 survivorsDischarge and 1 yearPersistent cognitive impairment at 1 year in bothTwo patients
Ye 2004 and Valdivieso 2006, Emerg Infect Dis21 and 20 survivorsUp to 11 yearsNeutralizing antibodies stay high for yearsAntibodies, not proof of protection

Lungs and Breathing

CDC's clinician brief describes the turn as fast: "Survivors frequently become polyuric during convalescence and improve rapidly." Polyuric means passing large amounts of urine, as the fluid that flooded the lungs leaves the body. Getting out of hospital is not the same as getting back to normal, though, and CDC gives no time frame for full recovery from HPS.

The one study that measured lung function for years is Gracia and colleagues' comparison of survivors in New Mexico and Panama. It describes a convalescent phase with breathlessness on exertion for three to four weeks in all forms of HPS. In their survivors it lasted longer: one to two years after infection in 77% of the New Mexico group and 43% of the Panama group. Tests found reduced airflow through the small airways, air trapped in the lungs, and reduced gas transfer. Oddly, how badly airflow was reduced did not match how breathless people felt. In the Panama group, symptoms had resolved within three years "in most but not all patients," and the authors conclude that the breathlessness and reduced airflow resolve "in almost all patients."

Nine and fourteen people are very small numbers, recruited because they were available, with no comparison group. The study shows that slow recovery happens and is common; it cannot say how common.

Fatigue, Mood and Getting Back to Work

The newest data come from Chile (Valenzuela et al., Viruses 2025), a study of 21 survivors of Andes virus infection treated in intensive care between 2021 and 2024, 11 of them on ECMO (an artificial lung). Three to six months after falling ill, 13 of the 21 (61.9%) said they had not fully recovered. The most common symptoms at three months were fatigue (81%), problems with movement (71%), hair loss (67%), insomnia (62%), anxiety (57%), breathlessness (57%) and memory problems (52%). The median time back to work or school was 3.5 months among the 17 for whom it was recorded.

Two cautions. Every person in that study had been in intensive care, and a long stay in intensive care causes weakness, poor sleep and anxiety whatever put you there, so the study cannot separate the virus from the treatment. And it ends at six months, so it says nothing about the second year.

On memory and thinking, the evidence is two people. Hopkins and colleagues tested two US survivors at discharge and again at one year and found "persistent cognitive impairments at 1 year" in both. That is a reason to mention memory problems to a doctor, not a measure of how often they happen.

Kidneys

HPS is a lung disease, and kidney damage was not thought to follow it. Pergam and colleagues checked, following 30 New Mexico survivors with yearly tests from a median of 7.4 months after discharge. Half (15 of 30) had more than 150 mg of protein in a 24-hour urine collection at some point, and 53% met a definition of chronic kidney disease. Those who had been on ECMO had fewer kidney findings. The authors concluded only that "renal sequelae may occur in HCPS": with no comparison group, they could not show the virus caused what they found. The kidney form of hantavirus, HFRS, is a different disease, covered below.

The Five-Year Figures You May See Quoted

Some websites give precise five-year percentages for US survivors: how many had reduced lung function, fatigue or memory problems. They trace back to a 2005 conference presentation on the University of New Mexico survivor programme, reported in medical trade news. The same programme's antibody paper (Ye et al., 2004) says its clinical results "will be reported separately." Only the kidney results appear to have reached a peer-reviewed journal (Pergam, above). The lung and fatigue percentages never did, so we don't repeat them here.

Can You Get Hantavirus Twice?

No second infection with the same hantavirus has been documented. Our PubMed search (November 2026) found no reported case, and the longest follow-ups looked for one:

  • Sin Nombre, United States. Ye and colleagues measured neutralizing antibodies in 21 survivors. "Even 1,000 days after admission to the hospital, 6 of 10 patients had titers of 800 or higher," and one sample still had 3,200 after more than 1,400 days.
  • Sin Nombre and Andes. Valdivieso and colleagues sampled 20 survivors from 8 months to 11 years after illness. Titers showed no clear decline with time, reaching 1:1,600 at 11 years. Antibodies against Andes virus did not neutralize Sin Nombre well, or the reverse.
  • Andes, Chile. Virus-specific T cells, the immune system's other long memory, were still detectable up to 13 years after infection (Manigold et al., PLoS Pathog 2010).
  • Puumala, Germany. In 156 people followed up to 20 years after the European kidney form, antibodies "remained detectable in all participants," and "No IgM antibodies or cases of reinfection were identified" (Kraft et al., Nephrol Dial Transplant 2026). A 2026 report from Austria is titled "Twenty-one years, twenty hospitals, zero reinfections."

Two honest limits. Lasting antibodies make reinfection unlikely, but no study was designed to measure protection directly. And because the antibodies are virus-specific, immunity to one hantavirus may not protect against another. That matters only for someone who moves between the Americas and Europe or Asia, or between the regions of Sin Nombre and Andes virus. CDC, WHO and ECDC say nothing about reinfection either way.

Are Survivors Contagious?

Sin Nombre virus (the US): no. CDC says Andes virus "is the only type of hantavirus that is known to spread person-to-person," and Ye and colleagues found no viral RNA in any survivor's convalescent blood sample.

Andes virus (Chile and Argentina): it spreads between people during the illness, and what happens after recovery is not settled. In 131 Chilean patients, Ferrés and colleagues still found viral RNA after day 16 in 12% of gum-fluid samples and 11% of saliva samples. They tested only acute-phase samples for live virus, though, and found it in 18 of 43, so whether later samples can infect anyone is unknown. In one survivor, Andes virus RNA persisted in semen for at least 71 months, with few mutations, "suggesting limited replication activity" (Züst et al., Viruses 2023). That is one patient. We found no CDC or WHO guidance on precautions after recovery.

The Kidney Form (HFRS): What Longer European Studies Show

The Old World form, hemorrhagic fever with renal syndrome, has larger and longer studies, mostly of Puumala virus, which causes its mildest version. CDC says of HFRS that "Complete recovery can take several weeks to months." The European cohorts add detail:

  • Recovery time. Among 1,132 former patients in northern Sweden, recovery took more than three months for 47% and more than six months for 32%. Fatigue scores were higher than in 915 people from the general population, "even 5 years following" infection (Furberg et al., 2019).
  • Blood pressure. In a Finnish cohort with controls, hypertension was 50% against 21% at five years (P = 0.020), and 39% against 17% at ten years, no longer significant (Miettinen et al., 2006).
  • Kidneys, longest follow-up. In 156 German patients a median of 13 years on, chronic kidney disease was found in 8%. The authors say their findings "do not support long-term kidney pathologies," and that whether the infection caused the high blood pressure found in 78% "remains uncertain" (Kraft et al., 2026).
  • Hormones. The two Finnish follow-ups disagree. One found a chronic hormone deficiency in 9 of 54 patients (17%) at a median of five years (Mäkelä et al., 2010). The other re-examined 47 patients at four to eight years and found none with late-onset pituitary failure caused by the infection (Partanen et al., 2016).

These figures are for a different, generally milder disease than HPS. They are not a guide to what happens after Sin Nombre or Andes virus, but they show what longer follow-up can find.

Frequently Asked Questions

How long does it take to recover from hantavirus?

The acute illness turns within days in people who survive it, but feeling normal again usually takes much longer. In the Chilean study (Valenzuela et al., 2025), the median return to work or school was 3.5 months, and 61.9% had not fully recovered at three to six months. In the US–Panama lung study (Gracia et al., 2010), breathlessness on exertion lasted one to two years in many survivors, and the authors found it resolves in almost all of them. For the European kidney form, CDC says complete recovery "can take several weeks to months."

Can you get hantavirus twice?

No second infection with the same hantavirus has been documented, and survivors keep neutralizing antibodies for at least 11 years. Immunity to one hantavirus may not protect against a different one.

Does hantavirus cause permanent lung damage?

Usually not, on the limited evidence. Small-airway changes and breathlessness were common for a year or two after HPS, and the one study that followed them found they resolve in almost all patients, though not every one. No study large enough to give a rate exists.

Is a hantavirus survivor contagious?

Not after Sin Nombre virus, the US strain, which does not spread between people. After Andes virus, viral RNA can linger in saliva and semen, but nobody has shown that a recovered person has passed the virus on.

Sources & References

  1. Centers for Disease Control and Prevention. Clinician Brief: Hantavirus Pulmonary Syndrome (HPS): "Survivors frequently become polyuric during convalescence and improve rapidly." cdc.gov
  2. Centers for Disease Control and Prevention. About Hantavirus: Andes virus "is the only type of hantavirus that is known to spread person-to-person"; for HFRS, "Complete recovery can take several weeks to months." cdc.gov
  3. Gracia F, Armien B, Simpson SQ, et al. Convalescent pulmonary dysfunction following hantavirus pulmonary syndrome in Panama and the United States. Lung 2010;188(5):387–91. doi:10.1007/s00408-010-9245-4
  4. Valenzuela G, Barahona K, Rojas C, et al. Beyond ECMO survival: long-term symptom burden and quality-of-life impairment in hantavirus cardiopulmonary syndrome survivors. Viruses 2025;17(9):1241. doi:10.3390/v17091241
  5. Pergam SA, Schmidt DW, Nofchissey RA, et al. Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am J Trop Med Hyg 2009;80(2):279–85. PubMed 19190227
  6. Hopkins RO, Larson-Lohr V, Weaver LK, Bigler ED. Neuropsychological impairments following hantavirus pulmonary syndrome. J Int Neuropsychol Soc 1998;4(2):190–6. PubMed 9529829
  7. Ye C, Prescott J, Nofchissey R, Goade D, Hjelle B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis 2004;10(3):478–82. doi:10.3201/eid1003.020821
  8. Valdivieso F, Vial P, Ferres M, et al. Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Emerg Infect Dis 2006;12(1):166–8. doi:10.3201/eid1201.050930
  9. Manigold T, Mori A, Graumann R, et al. Highly differentiated, resting Gn-specific memory CD8+ T cells persist years after infection by Andes hantavirus. PLoS Pathog 2010;6(2):e1000779. PubMed 20174562
  10. Ferrés M, Martínez-Valdebenito C, Henriquez C, et al. Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study. Lancet Infect Dis 2024;24(7):775–82. doi:10.1016/S1473-3099(24)00142-7
  11. Züst R, Ackermann-Gäumann R, Liechti N, et al. Presence and persistence of Andes virus RNA in human semen. Viruses 2023;15(11):2266. doi:10.3390/v15112266
  12. Kraft L, Oberacker T, Schwab A, et al. Clinical course up to 20 years after hantavirus infection. Nephrol Dial Transplant 2026;41(5):859–65. doi:10.1093/ndt/gfaf212
  13. Geiger C, Kriegl L, Krause R, Hatzl S. Twenty-one years, twenty hospitals, zero reinfections: Puumala virus follow-up in Styria, Austria. Clin Microbiol Infect 2026 (online ahead of print). doi:10.1016/j.cmi.2026.08.017
  14. Furberg M, Anticona C, Schumann B. Post-infectious fatigue following Puumala virus infection. Infect Dis (Lond) 2019;51(7):519–26. doi:10.1080/23744235.2019.1605191
  15. Miettinen MH, Mäkelä SM, Ala-Houhala IO, et al. Ten-year prognosis of Puumala hantavirus-induced acute interstitial nephritis. Kidney Int 2006;69(11):2043–8. doi:10.1038/sj.ki.5000334
  16. Mäkelä S, Jaatinen P, Miettinen M, et al. Hormonal deficiencies during and after Puumala hantavirus infection. Eur J Clin Microbiol Infect Dis 2010;29(6):705–13. PubMed 20397036
  17. Partanen T, Koivikko M, Leisti P, et al. Long-term hormonal follow-up after human Puumala hantavirus infection. Clin Endocrinol (Oxf) 2016;84(1):85–91. doi:10.1111/cen.12863
  18. Fama F, Molà F, Rizzo A, et al. Andes virus-associated cardiopulmonary syndrome: diagnostic approaches, clinical management, and evidence gaps — a scoping review. Clin Microbiol Infect 2026;32(9):1435–47: "Long-term outcomes are poorly characterized." PubMed 42323110